Breaking News Instant updates and real-time market news.

BMY

Bristol-Myers

$54.66

0.74 (1.37%)

17:19
10/03/16
10/03
17:19
10/03/16
17:19

Bristol-Myers Squibb to present Opdivo, Yervoy data at ESMO congress

Bristol-Myers Squibb announced new data across eight tumor types evaluating Opdivo and Yervoy as monotherapy or in combination, as well as new assets, to be presented at the 2016 European Society for Medical Oncology Congress in Copenhagen, Denmark from October 7-11. Data presented at this congress underscore the company's commitment to its portfolio and to discover the next wave of transformational Immuno-Oncology medicines, including combination therapies, for difficult-to-treat cancers. "Bristol-Myers Squibb continues to lead the scientific understanding of Immuno-Oncology with an extensive portfolio and a differentiated clinical development program where we have set a high bar of success to look for clear and differentiated improvements over currently available therapies," said Fouad Namouni, M.D., head of development, Oncology, Bristol-Myers Squibb. "We remain focused on expanding the use of the Opdivo and Yervoy combination to more tumors, and bringing forward novel agents and combination regimens in earlier lines of therapy, to help even more patients with cancer."

  • 09

    Oct

  • 27

    Oct

  • 31

    Oct

  • 06

    Nov

BMY Bristol-Myers
$54.66

0.74 (1.37%)

09/12/16
JEFF
09/12/16
NO CHANGE
Target $57
JEFF
Hold
Jefferies cuts Bristol-Myers price target, upgrades AstraZeneca
Jefferies analyst Jeffrey Holford lowered his price target for Bristol-Myers Squibb (BMY) to $57 from $69 saying the stock is positioned for a "rough mid term ride." The analyst sees a "difficult catalyst" set for Bristol shares with "numerous" upcoming competitor read-outs in non-small cell lung cancer. The market could see worse than expected data from Bristol's CM-026 and CM-568 studies as well as better than expected data from AstraZeneca's (AZN) MYSTIC study and Roche's (RHHBY) Chemo-IO studies in the first half of 2017, Holford tells investors in a research note. He keeps a Hold rating on Bristol and upgraded this morning AstraZeneca to Buy from Hold. Holford prefers Astra for its immunology exposure.
09/20/16
SBSH
09/20/16
NO CHANGE
Target $70
SBSH
Buy
Bristol-Myers price target lowered to $70 from $75 at Citi
In a research note titled "Brace Yourself. Attractive Valuation but No Near-Term Respite.," Citi analyst Andrew Baum lowered his price target for shares of Bristol-Myers Squibb to $70 from $75. The analyst lowered his earnings forecasts by up to 8% to reflect the "limited supportive data" in the non-small cell lung cancer indication. Baum keeps a Buy rating on the shares as he views the valuation as attractive. He points out, however, the near-term news-flow is likely to be negative.
09/27/16
PIPR
09/27/16
NO CHANGE
Target $62
PIPR
Neutral
Bristol-Myers price target lowered to $62 from $65 at Piper Jaffray
Piper Jaffray analyst Richard Purkiss lowered his price target for Bristol-Myers Squibb (BMY) to $62 saying he sees the company ceding Opdivo's early-mover advantage in lung cancer to competitors. The analyst expects to see details from Roche's (RHHBY) positive OAK trial of Tecentriq vs. docetaxel in non-small cell lung cancer at the upcoming ESMO meeting. Purkiss also expects to see details from Merck's (MRK) positive KEYNOTE-024 trial of Keytruda. The analyst lowered his post-2016 Opdivo forecasts and reiterates a Neutral rating on Bristol shares.
09/28/16
ROTH
09/28/16
NO CHANGE
Target $23
ROTH
Buy
Nektar price target raised to $23 from $19 at Roth Capital
Roth Capital analyst Michael Higgins raised his price target for Nektar (NKTR) to $23 from $19 after the company and Bristol-Myers (BMY) announced a clinical collaboration to evaluate the combination of the latter's anti-PD-1 antibody, Opdivo, with NKTR-214. The analyst reiterates a Buy rating on Nektar's shares.

TODAY'S FREE FLY STORIES

FRGI

Fiesta Restaurant

$25.95

-0.4 (-1.52%)

17:37
02/27/17
02/27
17:37
02/27/17
17:37
Hot Stocks
Fiesta Restaurant suspends sale evaluation process »

For the past four months,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

IPWR

Ideal Power

$2.40

-0.03 (-1.23%)

17:25
02/27/17
02/27
17:25
02/27/17
17:25
Earnings
Ideal Power reports Q4 EPS (29c), consensus (29c) »

Reports Q4 revenue $400K…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

KRA

Kraton Performance

$27.49

0.68 (2.54%)

17:25
02/27/17
02/27
17:25
02/27/17
17:25
Earnings
Kraton Performance reports Q4 EPS 29c, consensus 33c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

  • 07

    Mar

FLGT

Fulgent Genetics

$11.46

0.23 (2.05%)

17:19
02/27/17
02/27
17:19
02/27/17
17:19
Earnings
Fulgent Genetics reports Q4 EPS 6c, consensus 4c »

Reports Q4 revenue $5.9M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ONB

Old National Bancorp

$18.65

-0.05 (-0.27%)

, FMER

FirstMerit

17:18
02/27/17
02/27
17:18
02/27/17
17:18
Hot Stocks
Old National names Michael Woods principal accounting officer »

Old National Bancorp…

ONB

Old National Bancorp

$18.65

-0.05 (-0.27%)

FMER

FirstMerit

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WNC

Wabash

$21.06

0.21 (1.01%)

17:17
02/27/17
02/27
17:17
02/27/17
17:17
Syndicate
Breaking Syndicate news story on Wabash »

Wabash files automatic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ANTH

Anthera

$0.71

0.0142 (2.05%)

17:15
02/27/17
02/27
17:15
02/27/17
17:15
Earnings
Anthera reports Q4 EPS (36c), consensus (41c) »

The company ended the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNJ

Johnson & Johnson

$122.40

-0.33 (-0.27%)

17:13
02/27/17
02/27
17:13
02/27/17
17:13
Hot Stocks
Johnson & Johnson: DOJ inquires on Olysio, Massachusetts probes non-profit aid »

Johnson & Johnson…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 09

    Mar

  • 14

    Mar

  • 27

    Mar

ITGR

Integer

$36.95

0.55 (1.51%)

17:12
02/27/17
02/27
17:12
02/27/17
17:12
Hot Stocks
Integer announces Gary Haire joins company as CFO »

Integer Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

SHLM

A. Schulman

$33.75

0.05 (0.15%)

17:12
02/27/17
02/27
17:12
02/27/17
17:12
Hot Stocks
A. Schulman to open distribution center at Stryker, Ohio plant »

A. Schulman, Inc.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Mar

SWX

Southwest Gas

$85.54

0.24 (0.28%)

17:10
02/27/17
02/27
17:10
02/27/17
17:10
Earnings
Southwest Gas reports Q4 EPS $1.37, consensus $1.35 »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DERM

Dermira

$34.18

0.98 (2.95%)

17:09
02/27/17
02/27
17:09
02/27/17
17:09
Hot Stocks
Dermira to present data from DRM04, olumacostat glasaretil clinical programs »

Dermira announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

ALB

Albemarle

$92.46

-0.47 (-0.51%)

17:08
02/27/17
02/27
17:08
02/27/17
17:08
Earnings
Albemarle sees FY17 adjusted EPS $4.00-$4.25, consensus $4.07 »

Sees FY17 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

  • 16

    Mar

ALB

Albemarle

$92.46

-0.47 (-0.51%)

17:06
02/27/17
02/27
17:06
02/27/17
17:06
Earnings
Albemarle reports Q4 adjusted cont ops EPS 78c, consensus 73c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

  • 16

    Mar

RAIL

FreightCar America

$14.60

-0.04 (-0.27%)

17:06
02/27/17
02/27
17:06
02/27/17
17:06
Earnings
FreightCar America reports Q4 EPS 1c, consensus 14c »

Reports Q4 revenue $…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

ZTO

ZTO Express

$14.57

0.42 (2.97%)

17:05
02/27/17
02/27
17:05
02/27/17
17:05
Earnings
ZTO Express sees Q1 revenue $360M-$374.4M, consensus $380.54M »

Representing a 27.6% to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

ZTO

ZTO Express

$14.57

0.42 (2.97%)

17:03
02/27/17
02/27
17:03
02/27/17
17:03
Earnings
ZTO Express reports Q4 EPS 15c, consensus 16c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

WUBA

58.com

$32.49

0.52 (1.63%)

17:02
02/27/17
02/27
17:02
02/27/17
17:02
Earnings
Breaking Earnings news story on 58.com »

58.com sees Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

GLAD

Gladstone Capital

$9.22

0.1 (1.10%)

17:01
02/27/17
02/27
17:01
02/27/17
17:01
Hot Stocks
Gladstone Capital announces investment in unified communications business »

Gladstone Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WUBA

58.com

$32.49

0.52 (1.63%)

17:01
02/27/17
02/27
17:01
02/27/17
17:01
Earnings
58.com reports Q4 adjusted EPS 0c, consensus (12c) »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

PRGO

Perrigo

$84.68

0.25 (0.30%)

16:57
02/27/17
02/27
16:57
02/27/17
16:57
Hot Stocks
Perrigo down 11% after results, FY17 guidance, CFO change »

In after-hours trading,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 21

    Mar

STZ

Constellation Brands

$157.80

-1.05 (-0.66%)

16:56
02/27/17
02/27
16:56
02/27/17
16:56
Hot Stocks
Breaking Hot Stocks news story on Constellation Brands »

Soroban Capital reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APPF

AppFolio

$25.05

1.25 (5.25%)

16:55
02/27/17
02/27
16:55
02/27/17
16:55
Earnings
Breaking Earnings news story on AppFolio »

AppFolio sees FY17…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

RDN

Radian Group

16:55
02/27/17
02/27
16:55
02/27/17
16:55
Syndicate
Breaking Syndicate news story on Radian Group »

Radian Group files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APPF

AppFolio

$25.05

1.25 (5.25%)

16:54
02/27/17
02/27
16:54
02/27/17
16:54
Earnings
AppFolio reports Q4 EPS (4c), consensus (7c) »

Reports Q4 revenue $28M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.